January 15, 2025

ExoMira appoints Dr. Alex Le as Executive Advisor and Board Member, bolstering the company’s strategic growth, commercialization planning, and industry connectivity as it scales its pancancer immunotherapy platform.

January 5, 2025

ExoMira joins NIH-funded Multi-PI R01 grant led by co-founders Drs. Fang and Liu to develop dual-efficacy therapies for breast cancer.

November 13, 2024

Dr. Huiping Liu presented research on CTC cluster plasticity at EACR Liquid Biopsies 2024, reinforcing ExoMira’s scientific foundation in metastasis biology.

June 15, 2024

Dr. Huiping Liu has been named a Chan Zuckerberg Biohub Chicago Investigator, receiving multiyear funding to support innovative cancer research aligned with ExoMira’s mission.

October 23, 2024

ExoMira co-founder Dr. Huiping Liu chaired and presented at the 26th Lynn Sage Symposium, showcasing CTC-based strategies for targeting metastatic breast cancer.

April 9, 2024

ExoMira Co-Founder Dr. Huiping Liu presented on CTC plasticity and dormancy at a major AACR 2024 symposium, advancing visibility of the company’s science.